Search

Your search keyword '"Simpson, E. Rand"' showing total 171 results
Start Over Author "Simpson, E. Rand"
171 results on '"Simpson, E. Rand"'

2. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma

Author

Gallie, Brenda L., Simpson, E. Rand, Saakyan, Svetlana, Amiryan, Anush, Valskiy, Vladimir, Finger, Paul T., Chin, Kimberly J., Semenova, Ekaterina, Seregard, Stefan, Fili, Maria, Wilson, Matthew, Haik, Barrett, Caminal, Jose M., Català, Jaume, Gutierrez, Cristina, Pelayes, David E., Folgar, Anibal Martín, Jager, Martine J., Dogrusöz, Mehmet, Luyten, Gregorius P.M., Singh, Arun, Schachat, Andrew P., Suzuki, Shigenobu, and Aihara, Yukiko

Published
2016
Full Text
View/download PDF

4. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma

Author

Simpson, E. Rand, Gallie, Brenda, Laperrierre, Normand, Beiki-Ardakani, Akbar, Kivelä, Tero, Raivio, Virpi, Heikkonen, Jorma, Desjardins, Laurence, Dendale, Remi, Mazal, Alexandro, Bornfeld, Norbert, Sauerwein, Wolfgang, Flüehs, Dirk, Brualla, Lorenzo, Honavar, Santosh G., Reddy, Vijay Anand P., Suzuki, Shigenobu, Murakami, Naoya, Saakyan, Svetlana, Valskiy, Vladimir, Amiryan, Anush, Seregard, Stefan, All-Eriksson, Charlotta, Hjelmqvist, Lars, Lundell, Göran, Sinclair, Georges, Lundell, Marie, Damato, Bertil, Errington, R Doug, Mayles, Philip, Mayles, Helen, Bergstrom, Chris, Grossniklaus, Hans, Crocker, Ian, Butker, Elizabeth, Wilson, Matthew, Haik, Barrett, Geischen, Holger, Patra, Pradeep, Duker, Jay, Mignano, John, Rivard, Mark, Finger, Paul T., Semenova, Ekaterina, Choi, Walter, and Kalach, Nina I.

Published
2014
Full Text
View/download PDF

6. Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma

Author

Onken, Michael D., Worley, Lori A., Char, Devron H., Augsburger, James J., Correa, Zelia M., Nudleman, Eric, Aaberg, Thomas M., Jr., Altaweel, Michael M., Bardenstein, David S., Finger, Paul T., Gallie, Brenda L., Harocopos, George J., Hovland, Peter G., McGowan, Hugh D., Milman, Tatyana, Mruthyunjaya, Prithvi, Simpson, E. Rand, Smith, Morton E., Wilson, David J., Wirostko, William J., and Harbour, J. William

Published
2012
Full Text
View/download PDF

13. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma

Author

Simpson, E. Rand, Gallie, Brenda L., Saakyan, Svetlana, Amiryan, Anush, Finger, Paul T., Chin, Kimberly J., Seregard, Stefan, Fili, Maria, Wilson, Matthew, Haik, Barrett, Caminal, Jose M., Catala, Jaume, Pelayes, David E., Folgar, Anibal M., Jager, Martine, Dogrusöz, Mehmet, Singh, Arun, Schachat, Andrew, Suzuki, Shigenobu, and Aihara, Yukiko

Published
2015
Full Text
View/download PDF

20. List of contributors

Author

Anderson, Lynn D, primary, Barnebey, Howard S, additional, Berlin, Michael S, additional, Ehlers, William H, additional, Epstein, Daniel, additional, Evans, Peter Y, additional, Faye, Eleanor E, additional, Fiol-Silva, Zoraida, additional, Freeman, Joseph D, additional, Gilbert, Michael L, additional, Hackel, Richard E, additional, Levin, Alex V, additional, Mártonyi, Csaba L, additional, Meltzer, Gerald E, additional, Mills, Richard P, additional, Morgan, Rod A, additional, Pavlin, Charles J, additional, Rakow, Phyllis L, additional, Roth, Hans-Walter, additional, Salim, A Ghani, additional, Simpson, E Rand, additional, Stein, Rebecca L, additional, Sterns, Gwen K, additional, Waldbaum, Leonard N, additional, Ward, Michael A, additional, Jones, Melissa A, additional, and Mandelcorn, Efrem D, additional

Published
2013
Full Text
View/download PDF

29. Patients presenting with metastases: stage IV uveal melanoma, an international study

Author

Garg, Gaurav, primary, Finger, Paul T, additional, Kivelä, Tero T, additional, Simpson, E Rand, additional, Gallie, Brenda L, additional, Saakyan, Svetlana, additional, Amiryan, Anush G, additional, Valskiy, Vladimir, additional, Chin, Kimberly J, additional, Semenova, Ekaterina, additional, Seregard, Stefan, additional, Filì, Maria, additional, Wilson, Matthew, additional, Haik, Barrett, additional, Caminal, Josep Maria, additional, Catala-Mora, Jaume, additional, Gutiérrez, Cristina, additional, Pelayes, David E, additional, Folgar, Anibal Martin, additional, Jager, Martine Johanna, additional, Doğrusöz, Mehmet, additional, Luyten, Gregorius P M, additional, Singh, Arun D, additional, and Suzuki, Shigenobu, additional

Published
2021
Full Text
View/download PDF

31. Patients presenting with metastases: stage IV uveal melanoma, an international study.

Author

Garg, Gaurav, Finger, Paul T., Kivelä, Tero T., Simpson, E. Rand, Gallie, Brenda L., Saakyan, Svetlana, Amiryan, Anush G., Valskiy, Vladimir, Chin, Kimberly J., Semenova, Ekaterina, Seregard, Stefan, Filì, Maria, Wilson, Matthew, Haik, Barrett, Caminal, Josep Maria, Catala-Mora, Jaume, Gutiérrez, Cristina, Pelayes, David E., Folgar, Anibal Martin, and Jager, Martine Johanna

Abstract

Objective To analyse ocular and systemic findings of patients presenting with systemic metastasis. Methods and analysis It is an international, multicentre, internet-enabled, registry-based retrospective data analysis. Patients were diagnosed between 2001 and 2011. Data included: primary tumour dimensions, extrascleral extension, ciliary body involvement, American Joint Committee on Cancer (AJCC)-tumour, node, metastasis staging, characteristics of metastases. Results Of 3610 patients with uveal melanoma, 69 (1.9%; 95% CI 1.5 to 2.4) presented with clinical metastasis (stage IV). These melanomas originated in the iris, ciliary body and choroid in 4%, 16% and 80% of eyes, respectively. Using eighth edition AJCC, 8 (11%), 20 (29%), 24 (35%), and 17 (25%) belonged to AJCC T-categories T1-T4. Risk of synchronous metastases increased from 0.7% (T1) to 1.5% (T2), 2.6% (T3) and 7.9% (T4). Regional lymph node metastases (N1a) were detected in 9 (13%) patients of whom 6 (67%) had extrascleral extension. Stage of systemic metastases (known for 40 (59%) stage IV patients) revealed 14 (35%), 25 (63%) and 1 (2%) had small (M1a), medium-sized (M1b) and large-sized (M1c) metastases, respectively. Location of metastases in stage IV patients were liver (91%), lung (16%), bone (9%), brain (6%), subcutaneous tissue (4%) and others (5%). Multiple sites of metastases were noted in 24%. Compared with the 98.1% of patients who did not present with metastases, those with synchronous metastases had larger intraocular tumours, more frequent extrascleral extension, ciliary body involvement and thus a higher AJCC T-category. Conclusions Though higher AJCC T-stage was associated with risk for metastases at diagnosis, even small T1 tumours were stage IV at initial presentation. The liver was the most common site of metastases; however, frequent multiorgan involvement supports initial whole-body staging. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma

Author

Jain, Puneet, Finger, Paul T, Damato, Bertil, Coupland, Sarah E, Heimann, Heinrich, Kenawy, Nihal, Brouwer, Niels J, Marinkovic, Marina, Van Duinen, Sjoerd G, Caujolle, Jean Pierre, Maschi, Celia, Seregard, Stefan, Pelayes, David, Folgar, Martin, Yousef, Yacoub A, Krema, Hatem, Gallie, Brenda, Calle-Vasquez, Alberto, Albert, Daniel M, Amiryan, Anush G, Saakyan, Svetlana, Auw-Haedrich, Claudia, Baker, Diane, Barnhill, Raymond, Caminal, Jose M, Caroll, William L, Cassoux, Nathalie, Desjardins, Laurence G, Doz, Francois, Pierron, Gaelle, Catala-Mora, Jaume, Chantada, Guillermo, Chevez-Barrios, Patricia, Conway, R Max, Damato, Bertil E, Demirci, Hakan, Dutton, Jonathan J, Esmaeli, Bita, Prieto, Victor G, Williams, Michelle, Gallie, Brenda L, Graue, Gerardo F, Grossniklaus, Hans E, Heegaard, Steffen, Holbach, Leonard M, Honavar, Santosh G, Jager, Martine J, Kivela, Tero, Kujala, Emma, Lumbroso-Le Rouic, Livia, Mallipatna, Ashwin C, Modorati, Giulio M, Munier, Francis L, Murray, Timothy G, Pavlick, Anna C, Pe'er, Jacob, Pelayes, David E, Rodriguez, Manuel Jorge, Sauerwein, Wolfgang AG, Semenova, Ekaterina, Shields, Carol, Simpson, E Rand, Singh, Arun D, Suzuki, Shigenobu, Washington, Mary Kay, White, Valerie A, Wilson, Mathew W, Wittekind, Christian W, Yin, Vivian, Ophthalmic, Amer Joint Comm Canc, Department of Ophthalmology and Otorhinolaryngology, Silmäklinikka, HUS Head and Neck Center, Clinicum, HUS Psychiatry, and Department of Psychiatry

Subjects
medicine.medical_specialty, Medizin, 01 natural sciences, Metastasis, MALIGNANT-MELANOMA, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, Risk of mortality, medicine, MANAGEMENT, 7TH EDITION, 3125 Otorhinolaryngology, ophthalmology, 0101 mathematics, Cancer staging, AJCC staging system, business.industry, Mortality rate, 010102 general mathematics, Hazard ratio, medicine.disease, 3. Good health, PROGNOSTIC VALUE, Ophthalmology, 030221 ophthalmology & optometry, business, Conjunctival Melanoma, SYSTEM
Abstract

This case series assesses whether the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual can be used to accurately estimate mortality rates of conjunctival melanoma. Key PointsQuestionCan the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual for conjunctival melanoma be used to accurately estimate metastasis and mortality rates? FindingsIn this case series of 288 patients, there was a significantly higher cumulative mortality rate among patients with cT2 and cT3 conjunctival melanoma compared with those presenting with cT1 conjunctival melanoma. MeaningHigher T-staged tumors were associated with both an earlier and greater incidence of metastasis; therefore, the results from this multicenter, international registry study support the use of the eighth edition AJCC staging system for conjunctival melanoma. ImportanceEye cancer staging systems used for standardizing patient care and research need to be validated. ObjectiveTo evaluate the accuracy of the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual in estimating metastatis and mortality rates of conjunctival melanoma. Design, Setting, and ParticipantsThis international, multicenter, registry-based case series pooled data from 10 ophthalmic oncology centers from 9 countries on 4 continents. A total of 288 patients diagnosed with conjunctival melanoma from January 1, 2001, to December 31, 2013, were studied. Data analysis was performed from July 7, 2018, to September 11, 2018. InterventionsTreatments included excision biopsy, cryotherapy, topical chemotherapy, radiation therapy, enucleation, and exenteration. Main Outcomes and MeasuresMetastasis rates and 5-year and 10-year Kaplan-Meier mortality rates according to the clinical T categories and subcategories of the eighth edition of the AJCC Cancer Staging Manual. ResultsA total of 288 eyes from 288 patients (mean [SD] age, 59.7 [16.8] years; 147 [51.0%] male) with conjunctival melanoma were studied. Clinical primary tumors (cT) were staged at presentation as cT1 in 218 patients (75.7%), cT2 in 34 (11.8%), cT3 in 15 (5.2%), and cTx in 21 (7.3%). There were no T4 tumors. Pathological T categories (pT) were pTis in 43 patients (14.9%), pT1 in 169 (58.7%), pT2 in 33 (11.5%), pT3 in 12 (4.2%), and pTx in 31 (10.8%). Metastasis at presentation was seen in 5 patients (1.7%). Metastasis during follow-up developed in 24 patients (8.5%) after a median time of 4.3 years (interquartile range, 2.9-6.0 years). Of the 288 patients, 29 died (melanoma-related mortality, 10.1%) at a median time of 5.3 years (interquartile range, 1.8-7.0 years). The cumulative rates of mortality among patients with cT1 tumors were 0% at 1 year, 2.5% (95% CI, 0.7%-7.7%) at 5 years, and 15.2% (95% CI, 8.1%-27.4%) at 10 years of follow-up; among patients with cT2 tumors, 0% at 1 year, 28.6% (95% CI, 12.9%-58.4%) at 5 years, and 43.6% (95% CI, 19.6%-77.9%) at 10 years of follow-up; and among patients with cT3 tumors, 21.1% (95% CI, 8.1%-52.7%) at 1 year of follow-up and 31.6% (95% CI, 13.5%-64.9%) at 5 years of follow-up. Patients with cT2 and cT3 tumors had a significantly higher cumulative mortality rate compared with those presenting with cT1 tumors (log-rank P

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results